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Introduction
Immune surveillance is mediated by both cellular and humoral immunities.
Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are major players in cell-mediated immunity against tumors or virus-infected cells. CTL and NK cells often share adhesion or costimulatory molecules, including CD2 and leukocyte function-associated antigen-1 (LFA-1; CD11a/CD18), CD27, 2B4, CD28, inducible costimulator (ICOS), NKG2D and others 1, 2 . These cell surface molecules not only mediate intercellular binding between these cytotoxic lymphocytes and target cells, but also participate in signal transduction for cytotoxicity and cytokine secretion 1, 3 .
DNAM-1 (CD226) is an adhesion molecule that is a member of immunoglobulin superfamily containing two Ig-like domains of the V-set [4] [5] [6] . DNAM-1 is a ~65 kDa glycoprotein expressed on the majority of NK cells, T cells, monocytes and platelets and a subset of B lymphocytes 4, 7, 8 . The monoclonal antibody (mAb) against DNAM-1 inhibited antigen-specific CTL-and NK cell-mediated cytolysis of some, but not all, tumor targets in vitro, suggesting that DNAM-1 is involved in cytotoxicity against certain tumor cells expressing the DNAM-1 ligand. Recently, we and others have identified Tahara-Hanaoka et al 4 the poliovirus receptor (PVR) CD155 and its family member CD112 (PVR-related family-2 (PRR-2), also called as nectin-2), as the ligands for human DNAM-1 9, 10 .
Ectopic expression of human CD155 and/or CD112 rendered tumor cell lines more susceptible to IL-2-activated T and NK cell-mediated cytotoxicity in vitro. While the human DNAM-1 ligands CD112 and CD155 are broadly distributed on epithelial and endothelial cells in many tissues 11, 12 , they are over-expressed on certain human tumors, including colorectal carcinomas 13 , myeloid leukemias 14 , and neuroblastomas 15 , suggesting that the DNAM-1 ligands expression is inducible by "stress" such as transformation and infection. However, it has still been an open question how the interaction of DNAM-1 with its ligands is involved in immune responses in vivo.
We have recently identified the murine homologues of DNAM-1 and its ligands 16 . In the present study, we investigated an in vivo role of DNAM-1 and DNAM-1 ligands on tumor immunosurveillance. Nakayama (Okayama University, Japan)), anti-mouse CD4 (GK1.5) and anti-NK1.1 (PK136) (obtained from ATCC (Manassas, VA) were used. The other mAbs used in this study were purchased from BD Biosciences (San Jose, CA). RMA cells stably expressing mouse CD112α and CD155 (RMA-CD112 and RMA-CD155, respectively) were established, as described previously 16 . Control RMA cells were also established by transducing pMX vector alone and this transduction was confirmed by genomic PCR for the vector backbone sequence, using the primers combination of 
ELISPOT assay
ELISPOT assay was performed with a mouse IFN-γ -specific ELISPOT kit (e-Bioscience, San Diego, CA) according to the manufacturer's instructions.
Splenocytes from naïve C57BL/6 mouse were used as an antigen presenting cells 
Immunohisotochemistry
Immunostaining was performed with some modifications as previously 
RESULTS

Expression of the DNAM-1 ligand on human poorly-differentiated gastric cancer
Recent evidences indicate that the DNAM-1 ligands CD155 and CD112 are over-expressed on certain human tumors, including colorectal carcinomas, neuroblastomas and myeloid leukemias [13] [14] [15] . We also investigated the expression of the DNAM-1 ligand CD112 on specimens from five patients with gastric cancer, including two well-differentiated and three poorly-differentiated histological types, and two patients with colon cancer. Immunohistochemical analyses demonstrated that CD112 was over-expressed preferentially in the poorly-, but not well-, differentiated histological type of gastric cancer (Fig 1a) . We could not clearly detect CD112 in the untransformed normal tissue area bordering transformed cancer tissue in each specimen.
To further assess whether CD112 is specifically expressed in poorly-differentiated cancer tissue but not in normal gastric tissue, we divided the gastric tissues resected under surgery into transformed and normal areas of slices and compared mRNA expression of CD112 in each patient by quantitative RT-PCR analysis.
As shown in Fig 1b, relative amount of CD112 mRNA expressions are about three Tahara-Hanaoka et al 13 times higher in the poorly-differentiated gastric cancer compared with that in normal gastric tissue in all the three patients. We also observed the over-expression of CD112 on colon cancer as well (Fig 1a) . These observations, along with the recent reports [13] [14] [15] , suggest that DNAM-1 ligands can be targets for tumor immunosurveillance in vivo.
RMA tumor expressing DNAM-1 ligands is rejected in mice
To investigate the in vivo consequences of DNAM-1 ligands expression on tumor cells, B6 mice were inoculated subcutaneously with a murine T cell lymphoma RMA transfected with control vector (RMA-mock) or CD112 (RMA-CD112). Whereas mice injected with 1 x 10 5 RMA-mock all developed tumors and died by 55 days after tumor inoculation, most mice rejected the same number of RMA-CD112 (Fig 2A) .
These recipient mice of RMA-CD112 survived significantly longer than those of RMA-mock (Fig 2A) . Similarly, most mice rejected 1 x 10 5 RMA trasfected with CD155 (RMA-CD115) and survived more than 175 days (Fig 2B) . Since all these RMA transfectants showed similar growth kinetics in vitro, as determined by BrdU (Fig 2C, D) . These results indicated that CD8+ T cells were essential for the rejection of DNAM-1 ligands-transduced RMA tumors.
Colonna and colleagues have recently identified the T cell-activated increased late expression (Tactile) (also called as CD96), which is expressed on activated T cells 18 , as another receptor ligand for human CD155 19 . However, it is unclear whether the mouse homologue of CD96 is also a receptor for mouse CD155 or CD112, although it
has not yet been identified. To confirm that DNAM-1, but not putative murine CD96, is responsible for the rejection of DNAM-1-ligands-expressing RMA tumors, we generated an anti-DNAM-1 mAb (TX42) that was able to block the ligand binding in vitro ( Fig 3A) . Mice were pretreated in vivo with TX42 mAb, which did not deplete T cells and NK cells in vivo (Fig 3B) , and then inoculated subcutaneously with RMA-CD155. Eight days after tumor inoculation when tumors had not yet grown enough to be visible on the skin, the skin regions was resected and subjected to histological analyses. Whereas RMA-mock substantially proliferated in the skin region, most RMA-CD155 appeared to be dead (Fig 3C) . However, pretreatment with anti-DNAM-1 mAb restored RMA-CD155 growth (Fig 3C) , and the survival of these mice was significantly shorter than that of mice pretreated with control Ig (Fig 3D) .
Similar results were observed in mice inoculated with RMA-CD112 (data not shown).
Because TX42 mAb did not affect the lymphocytes population in vivo, these results suggested an essential role of DNAM-1 on CD8+ T cells in the tumor rejection.
Induction of memory CD8+ T cells in mice inoculated with DNAM-1 ligand-expressing RMA
To investigate whether DNAM-1 ligands expression on RMA induces T cell-mediated immunological memory, mice that had previously rejected the CD155-tranfected RMA tumor cells were re-challenged with the parental RMA tumors 70 days after the first inoculation (Fig 4) . Whereas RMA-mock grew and killed all naïve mice after the first inoculation, they were rejected in all the mice that had once rejected RMA-CD155 (Fig 4) . However, depletion of CD8+ T cells with in vivo injection of anti-CD8 mAb before the re-challenge canceled the rejection of RMA (Fig   4) . These results suggest that CD8+ memory T cells specific for an RMA tumor-associated antigen were generated in mice inoculated with RMA-CD155.
RMA is a Rauscher murine leukemia virus-transformed cell line bearing H-2D b , which associates with a peptide derived from the gag leader (gagL) sequence of the virus recognized by CTL as an epitope 20, 21 . To investigate whether CD8+ T cells generated in mice inoculated with RMA-CD155 were specific to the gagL peptide, we 
DNAM-1-mediated signal induces maturation of CD8α+ dendritic cells
In a detailed study of mouse DNAM-1 expression on immune cells using our newly generated anti-DNAM-1 mAb, we found that a subset of CD11c+ cells also expressed DNAM-1.
Further examination demonstrated that DNAM-1 was preferentially expressed on CD8α+, rather than CD8α-, CD11c+ dendritic cells (DC) in spleen (Fig 5A) , suggesting that DNAM-1 ligands may stimulate also this subset of DC.
To examine this possibility, CD11c+ cells were purified from spleen by MACS sorting, 
CD4+ T cells are also involved in the tumor rejection
CD8α+ DC is a functionally specialized subpopulation (reviewed in Shortman, K., et al 22 ), which produces much higher level of IL-12 p70 than CD8α-DC population and is involved in Th1 differentiation from naïve helper T cells 23, 24 . Therefore, we (Fig 2A, G) . Similarly, the survival of mice deficient in MHC class II was significantly shorter than those of wild type mice after inoculation with RMA-CD112 (Fig 2A, F) .
DISCUSSION
The DNAM-1 ligands are constitutively expressed at low levels on epithelial and endothelial cells. In the present study, we have shown that the DNAM-1 ligand CD112 is over-expressed on human gastric and colon cancers. There are also evidences that the DNAM-1 ligands expression is up-regulated on human tumors, including colorectal carcinomas, neuroblastomas and myeloid leukemias [13] [14] [15] . These observations suggest that the DNAM-1 ligands expression may be inducible by "stress" One of the most notable findings in the present study was that CD8α+, but not CD8α-, DC substantially expressed DNAM-1 and cross-linking DNAM-1 with anti-DNAM-1 mAb induced maturation of CD8α+ DC in vitro. Importantly, the CD8α+ DC is a functionally specialized subpopulation (reviewed in 22 ). They produces much higher level of IL-12 p70 than CD8α-DC populations 23, 24 , resulting in differentiation of 
